<DOC>
	<DOCNO>NCT01131585</DOCNO>
	<brief_summary>This study design confirm efficacy safety laser photocoagulation adjunctive therapy ranibizumab 0.5 mg versus laser monotherapy patient visual impairment due Diabetic Macular Edema . A subgroup patient Proliferative Diabetic Retinopathy include evaluate efficacy safety laser photocoagulation adjunctive therapy ranibizumab 0.5 mg versus laser monotherapy population .</brief_summary>
	<brief_title>Safety Efficacy Ranibizumab Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Visual acuity impairment cause macular edema least one eye Type 1 type 2 diabetes mellitus Stable medication diabetes past 3 month Patients uncontrolled systemic ocular disease Laser photocoagulation study eye last 3 month Any history intraocular surgery study eye within past 3 month Blood pressure &gt; 160/100 mmHg Other protocol define inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Diabetic macular edema</keyword>
	<keyword>DME</keyword>
	<keyword>Proliferative diabetic retinopathy</keyword>
	<keyword>PDR</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>laser</keyword>
</DOC>